An introduction to burkitt lymphoma

Burkitt's Lymphoma

Volumn , Issue , 2013, Pages 1-33

  Magrath, Ian ^a,b  

^a INTERNATIONAL NETWORK FOR CANCER TREATMENT AND RESEARCH   (Belgium)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84907537031     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4313-1_1     Document Type: Editorial

References (119)

1. Davies JNP, Elmes S, Hutt M et al (1964) Cancer in an African community, 1897-1956. An analysis of the records of Mengo Hospital, Kampala, Uganda: Part 1. Br Med J 1(5379):336-341
2. Smith EC, Elmes BGT (1934) Malignant disease in natives of Nigeria. Ann Trop Med Parasitol 28:461-512
3. Davies JNP (1948) Reticuloendothelial tumours. E Afr Med J 25:117
4. Edington GM (1956) Malignant disease in the Gold Coast. Br J Cancer 10:41-54
5. Thijs A (1957) Considérations sur les tumeurs malignes des indigènes du Congo belge et du Ruanda-Urundi. A propos de 2,536 cas. Ann Soc Belg Med Trop 37:483-514
6. De Smet MP (1956) Observations cliniques de tumeurs malignes des tissus réticuloendothéliaux et des tissus hémolymphopoiétiques au Congo. Ann Soc Belg Med Trop 36:53-70
7. Burkitt D (1958) A sarcoma involving the jaws in African children. Br J Surg 46:218-223
8. O'Conor GT, Davies JNP (1960) Malignant tumors in African children with special reference to malignant lymphomas. J Pediatr 56:526-535
9. O'Conor G (1961) Malignant lymphoma in African children. Cancer. II. A pathological entity. Cancer 14:270-283
10. O'Conor G, Rappaport H, Smith EB (1965) Childhood lymphoma resembling Burkitt's tumor in the United States. Cancer 18:411-417
11. Dorfman RF (1965) Childhood lymphosarcoma in St Louis, Missouri, clinically and histologically resembling Burkitt's tumor. Cancer 18:418-430
12. Wright DH (1966) Burkitt's tumour in England. A comparison with childhood lymphosarcoma. Int J Cancer 1:503-514
13. Histopathological Definition of Burkitt's Lymphoma (1969) Bull World Health Org 40:601-607
14. Ziegler JL, Drew WL, Miner RC et al (1982) Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet 2:631-633
15. Magrath IT (1991) African Burkitt's lymphoma: history, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol 13:222
16. Wright DH (1964) Burkitt's tumour. A post-portem study of 50 cases. Br J Surg 51:245-251
17. Shepherd JJ, Wright DH (1967) Burkitt's tumour presenting as bilateral swelling of the breast in women of child-bearing age. Br J Surg 54:776-780
18. Orem J, Mbidde EK, Lambart B (2007) Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci 7:166-175
19. Burkitt D (1962) Determining the climatic limitations of a children's cancer common in Africa. Br Med J 2:1019-1026
20. Burkitt D (1962) A children's cancer dependent on climatic factors. Nature 194:232-234
21. Booth K, Burkitt DP, Bassett DJ et al (1967) Burkitt lymphoma in Papua New Guinea. Br J Cancer 21:657-664
22. Dalldorf G, Linsell CA, Marnhart FE, Martyn R (1964) An epidemiological approach to the lymphomas of African children and Burkitt's sarcoma of the jaws. Perspect Biol Med 7:435-449
23. Morrow RH, Kisuule A, Pike MC, Smith PG (1976) Burkitt's lymphoma in the Mengo districts of Uganda: epidemiological features and their relationship to malaria. J Natl Cancer Inst 56:479-483
24. Chêne A, Donati D, Guerreiro-Cacais AO (2007) A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog 3(6):e80
25. Simone O, Bejarano MT, Pierce SK (2011) TLRs innate immunereceptors and Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) CIDR1a-driven human polyclonal B-cell activation. Acta Trop 119(2-3):144-150
26. Moormann AM, Chelimo K, Sumba OP et al (2005) Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis 191:1233-1238
27. Njie R, Bell AI, Jia H et al (2009) The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children. J Infect Dis 199(1):31-38
28. Thorley-Lawson DA, Allday MJ (2008) The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 6(12):913-924
29. Peng SL (2005) Signaling in B cells via Toll-like receptors. Curr Opin Immunol 17:230
30. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709
31. Ruprecht CR, Lanzavecchia A (2006) Toll-like receptor stimulation as a third signal required for activation of human naïve B cells. Eur J Immunol 36:810
32. Edry E, Azulay-Debby H, Melamed D (2008) TOLL-like receptor ligands stimulate aberrant class switch recombination in early B cell precursors. Int Immunol 20(12):1575-1585
33. Ramiro AR, Jankovic M, Callen E et al (2006) Role of genomic instability and p53 in AID- induced c-myc-Igh translocations. Nature 440(7080):105-109
34. Jankovic M, Robbiani DF, Dorsett Y et al (2010) Role of the translocation partner in protection against AID-dependent chromosomal translocations. Proc Natl Acad Sci USA 107(1): 187-192
35. Gaidano G, Ballerini P, Gong JZ et al (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88(12):5413-5417
36. Bhatia KG, Gutiérrez MI, Huppi K et al (1992) The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. Cancer Res 52(15):4273-4276
37. Pasqualucci L, Bhagat G, Jankovic M (2008) AID is required for germinal center-derived lymphomagenesis. Nat Genet 40(1):108-112
38. Hillion S, Youinou P, Jamin C (2007) Peripheral expression of RAG in human B lymphocytes in normal and pathological conditions is dependent on interleukin-6. Autoimmun Rev 6:415-420
39. Wang YH, Diamond B (2008) B cell receptor revision diminishes the autoreactive B cell response after antigen activation in mice. J Clin Invest 118(8):2896-2907
40. Rainey JJ, Mwanda WO, Wairiumu P et al (2007) Spatial distribution of Burkitt's lymphoma in Kenya and association with malaria risk. Trop Med Int Health 12(8):936-943
41. Morrow RH Jr (1985) Epidemiological evidence for the role of falciparum malaria in the pathogenesis of Burkitt's lymphoma. IARC Sci Publ 60:177-186
42. Geser A, Brubaker G, Draper CC (1989) Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma. Am J Epidemiol 129(4):740-752
43. Epstein MA, Achong BG, Barr YM (1964) Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1(7335):702-703
44. Schulte-Holthausen H, zur Hausen H (1972) Epstein-Barr virus DNA in human tumor cells. Zentralbl Bakteriol Orig A 220(1):47-51
45. Reedman BM, Klein G (1973) Cellular localization of an Epstein-Barr virus (EBV)- associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer 11:499-520
46. Young LS, Rickinson AB (2004) Epstein-Barr virus: 40 years on. Nat Rev Cancer 4(10):757-768
47. Thorley-Lawson DA (2001) Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 1(1):75-82
48. Roughan JE, Thorley-Lawson DA (2009) The intersection of Epstein-Barr virus with the germinal center. J Virol 83(8):3968-3976
49. Long HM, Taylor GS, Rickinson AB (2011) Immune defence against EBV and EBV- associated disease. Curr Opin Immunol 23(2):258-264
50. Pajic A, Staege MS, Dudziak D, Schuhmacher M, Spitkovsky D, Eissner G, Brielmeier M, Polack A, Bornkamm GW (2001) Antagonistic effects of c-myc and Epstein-Barr virus latent genes on the phenotype of human B cells. Int J Cancer 93(6):810-816
51. Musso A, Migliore G, Zuccolin G et al (1984) Epstein-Barr anti-viral antibodies in childhood in relation to social status. Minerva Pediatr 36(1-2):9-16
52. Henle G, Henle W, Clifford P et al (1969) Antibodies to EB virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst 43:1147-1157
53. Evans AS, Niederman JC, McCollum RW (1968) Seroepidemiologic studies of infectious mononucleosis with EB virus. N Engl J Med 279(21):1121-1127
54. Miller G, Lisco H, Kohn HI, Stitt D, Enders JF (1971) Establishment of cell lines from normal adult human blood leukocytes by exposure to Epstein-Barr virus and neutralization by human sera with Epstein-Barr virus antibody. Proc Soc Exp Biol Med 137(4):1459-1465
55. Rowe M, Kelly GL, Bell AI, Rickinson AB (2009) Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol 19(6):377-388
56. Ressing ME, Horst D, Griffin BD et al (2008) Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin Cancer Biol 18(6):397-408
57. Moormann AM, Heller KN, Chelimo K et al (2009) Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer 124(7): 1721-1726
58. Geser A, de Thé G, Lenoir G, Day NE, Williams EH (1982) Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int J Cancer 29(4):397-400
59. Pavri R, Nussenzweig MC (2011) AID targeting in antibody diversity. Adv Immunol 110:1-26
60. Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB (2006) Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci USA 103(40):14935-14940
61. Kelly GL, Milner AE, Tierney RJ et al (2005) Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J Virol 79(16):10709-10717
62. Ziegler JL, Beckstead JA, Volberding PA et al (1984) Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med 311(9):565-570
63. Parkin DM, Garcia-Giannoli H, Raphael M et al (2000) Non-Hodgkin lymphoma in Uganda: a case-control study. AIDS 14(18):2929-2936
64. Flateau C, Le Loup G, Pialoux G et al (2011) Consequences of HIV infection on malaria and therapeutic implications: a systematic review. Lancet Infect Dis 11(7):541-556
65. Richard Y, Amiel C, Jeantils V et al (2010) Changes in blood B cell phenotypes and Epstein- Barr virus load in chronically human immunodeficiency virus-infected patients before and after antiretroviral therapy. J Infect Dis 202(9):1424-1434
66. Bonnet F, Jouvencel AC, Parrens M et al (2006) A longitudinal and prospective study of Epstein-Barr virus load in AIDS-related non-Hodgkin lymphoma. J Clin Virol 36(4): 258-263
67. Adjei AA, Armah HB, Gbagbo F et al (2008) Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa. BMC Infect Dis 8:111
68. Naresh KN, Raphael M, Ayers L et al (2011) Lymphomas in sub-Saharan Africa - what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research? Br J Haematol 10, 1365-2141
69. Zech L, Haglund U, Nilsson K et al (1976) Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer 17:47
70. Klein U, Tu Y, Stolovitzky GA, Keller JL et al (2003) Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci USA 100(5):2639-2644
71. Bellan C, Lazzi S, Hummel M et al (2005) Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 106(3): 1031-1036
72. Piccaluga PP, De Falco G, Kustagi M et al (2011) Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood 117(13):3596-3608
73. Lenze D, Leoncini L, Hummel M et al (2011) The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma. Leukemia 25:1869-1876. doi:10.1038/leu.2011.156
74. Magrath IT (1990) The pathogenesis of Burkitt's lymphoma. In: Klein G, Van de Woude G (eds) Recent Adv Cancer Res 55:133-270
75. Hummel M, Bentink S, Berger H et al (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354(23):2419-2430
76. Onnis A, De Falco G, Antonicelli G et al (2010) Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma. PLoS One 5(9). pii:e12960
77. Richter-Larrea JA, Robles EF, Fresquet V et al (2010) Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 116(14):2531-2542
78. Casellas R, Yamane A, Kovalchuk AL, Potter M (2009) Restricting activation-induced cytidine deaminase tumorigenic activity in B lymphocytes. Immunology 126(3):316-328
79. Pasqualucci L, Bhagat G, Jankovic M et al (2008) AID is required for germinal center-derived lymphomagenesis. Nat Genet 40(1):108-112
80. Robbiani DF, Bothmer A, Callen E et al (2008) AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 135(6):1028-1038
81. Nagy N, Klein G, Klein E (2009) To the genesis of Burkitt lymphoma: regulation of apoptosis by EBNA-1 and SAP may determine the fate of Ig-myc translocation carrying B lymphocytes. Semin Cancer Biol 19(6):407-410
82. Burkitt D (1967) Long-term remissions following one and two-dose chemotherapy for African lymphoma. Cancer 20:756-759
83. Clifford P (1967) Long term survival of patients with Burkitt's lymphoma. An assessment of treatment and other factors which may relate to survival. Cancer Res 27:2578
84. Ngu VA (1965) The African lymphoma (Burkitt tumour) survivals exceeding two years. Br J Cancer 19:101-107
85. Burkitt D (1967) Chemotherapy of jaw tumours. In: Treatment of Burkitt's tumour. Monograph series number 8, International Union Against Cancer, pp 94-104
86. Ziegler JL (1972) Chemotherapy of Burkitt's lymphoma. Cancer 30:1534-1540
87. Haddy TB, Adde MA, Magrath IT (1991) CNS involvement in small noncleaved-cell lymphoma: is CNS disease per se a poor prognostic sign? J Clin Oncol 9:1973-1982
88. Ngu VA (1972) Chemotherapy of Burkitt's tumor at the University of Ibadan, Nigeria. JAMA 222(9): 1166
89. Klein G, Clifford P, Klein E, Stjernswärd J (1966) Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci USA 55(6):1628-1635
90. Magrath IT, Ziegler JL (1976) Failure of BCG immunostimulation to affect the clinical course of Burkitt's lymphoma. Br Med J 1(6010):615-618
91. Magrath I, Lee YJ, Anderson T et al (1980) Prognostic factors in Burkitt's lymphoma: importance of total tumor burden. Cancer 45(6):1507-1515
92. Magrath IT (1974) Immunosuppression in Burkitt's lymphoma. I. Cutaneous reactivity to recall antigens: alterations induced by a tumour burden and by BCG administration. Int J Cancer 13(6):839-849
93. Ziegler JL, Bluming AZ, Fass L et al (1972) Relapse patterns in Burkitt's lymphoma. Cancer Res 32:1267-1272
94. Nkrumah FK, Perkins IV (1976) Burkitt's lymphoma: a clinical study of 110 patients. Cancer 37(2):671-676
95. Nkrumah FK, Perkins IV, Biggar RJ (1977) Combination chemotherapy in abdominal Burkitt's lymphoma. Cancer 40(4):1410-1416
96. Olweny CL, Katongole-Mbidde E, Kaddu-Mukasa A et al (1976) Treatment of Burkitt's lymphoma: randomized clinical trial of single-agent versus combination chemotherapy. Int J Cancer 17:436-440
97. Olweny CL, Atine I, Kaddu-Mukasa A et al (1977) Cerebrospinal irradiation of Burkitt's lymphoma. Failure in preventing central nervous system relapse. Acta Radiol Ther Phys Biol 16:225-231
98. Olweny CL, Katongole-Mbidde E, Otim D, Lwanga SK, Magrath IT, Ziegler JL (1980) Long-term experience with Burkitt's lymphoma in Uganda. Int J Cancer 26(3):261-266
99. Ziegler JL, Bluming AZ (1971) Intrathecal chemotherapy in Burkitt's lymphoma. Br Med J 3:508-512
100. Magrath IT, Lwanga S, Carswell W, Harrison N (1974) Surgical reduction of tumour bulk in management of abdominal Burkitt's lymphoma. Br Med J 2(5914):308-312
101. Norin T, Clifford P, Einhorn J et al (1971) Radiotherapy in Burkitt's lymphoma. Conventional or superfractionated radiation therapy in Burkitt lymphoma. Acta Radiol Ther Phys Biol 10:545
102. Norin T (1977) Radiation therapy in Burkitt's lymphoma. Long term results. Acta Radiol Ther Phys Biol 16:289-294
103. Berard CW (1985) Morphological definition of Burkitt's tumour: historical review and present status. IARC Sci Publ (60):31-35
104. Arseneau JC, Canellos GP, Banks PM, Berard CW, Gralnick HR, DeVita VT Jr (1975) American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival. Am J Med 58(3):314-321
105. Arseneau JC, Bagley CM, Anderson T, Canellos GP (1973) Hyperkalaemia, a sequel to chemotherapy of Burkitt's lymphoma. Lancet 6(1):10-14
106. Brereton HD, Anderson T, Johnson RE, Schein PS (1975) Hyperphosphatemia and hypocalcemia in Burkitt lymophoma. Complications of chemotherapy. Arch Intern Med 135:307-309
107. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL (1980) Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med 68(4):486-491
108. Ziegler JL, DeVita VT, Graw RG Jr, Herzig G, Leventhal BG, Levine AS, Pomeroy TC (1976) Combined modality treatment of American Burkitt's lymphoma. Cancer 38(6):2225-2231
109. Ziegler JL (1977) Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience. N Engl J Med 297(2):75-80
110. Appelbaum FR, Deisseroth AB, Graw RG Jr, Herzig GP, Levine AS, Magrath IT, Pizzo PA, Poplack DG, Ziegler JL (1978) Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse. Cancer 41(3):1059-1063
111. Anderson JR, Wilson JF, Jenkin DT, Meadows AT, Kersey J, Chilcote RR, Coccia P, Exelby P, Kushner J, Siegel S, Hammond D (1983) Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 308(10):559-565
112. Magrath IT, Janus C, Edwards BK, Spiegel R, Jaffe ES, Berard CW, Miliauskas J, Morris K, Barnwell R (1984) An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood 63:1102-1111
113. Magrath I, Adde M, Shad A et al (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934
114. Adde M, Shad A, Venzon D et al (1998) Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol 25 (2 suppl 4):S33-S39
115. Patte C, Michon J, Frappaz D et al (1994) Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults. Baillieres Clin Haematol 7:339-348
116. Reiter A, Schrappe M, Parwaresch R et al (1995) Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage-a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol 13:359-372
117. Linch DC (2012) Burkitt lymphoma in adults. Br J Haematol 156:693-703. doi: 10.1111/ j. 1365-2141.2011.08877.x
118. Mohamedbhai SG, Sibson K, Marafioti T et al (2011) Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. Br J Haematol 152(2):175-181. doi: 10.1111/ j. 1365-2141.2010.08447.x
119. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A (2010) Berlin-Frankfurt-Münster group. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 28:3115-3121